GlassScriptPhysician profile
Lalitha Nayak
NPI 1699803866
$11,199.17
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,817 · 2020: $54.25 · 2021: $145 · 2022: $425 · 2023: $332 · 2024: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $9,393.04 | 2019 | |
| Genentech USA, INC. | $514.43 | 2019-2023 | Hemlibra, Tecentriq, Alecensa |
| Novartis Pharmaceuticals Corporation | $199.14 | 2020-2024 | |
| Csl Behring | $111.95 | 2022 | |
| Genzyme Corporation | $100.07 | 2019-2024 | |
| Incyte Corporation | $90.72 | 2019-2024 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $85.07 | 2019-2023 | Lynparza, Calquence |
| Astellas Pharma US INC | $77.32 | 2019-2023 | Xospata |
| Amgen INC. | $75.49 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Seagen INC. | $47.59 | 2019-2023 | Tukysa |
| Aveo Pharmaceuticals, INC. | $46.97 | 2024 | |
| Merck Sharp & Dohme LLC | $43.40 | 2019-2024 | Keytruda |
| Daiichi Sankyo INC. | $41.32 | 2024 | Enhertu |
| Beigene USA, INC. | $38.37 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $36.66 | 2024 | Pyrukynd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.41 | 2019-2024 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $31.15 | 2019-2021 | |
| Lilly USA, LLC | $24.82 | 2022 | |
| Morphosys, US INC. | $23.65 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $23.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.24 | 2023 | Opdualag |
| Eisai INC. | $20.45 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.32 | 2019 | |
| Taiho Oncology, INC. | $19.39 | 2019 | |
| Pfizer INC. | $18.89 | 2023 | |
| Jazz Pharmaceuticals INC. | $18.60 | 2019 | |
| Adc Therapeutics America, INC. | $18.50 | 2024 | |
| Dova Pharmaceuticals | $13.28 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalitha Nayak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.